Lung · 20 Nov 2026
Effect of Nerandomilast in US Patients with Progressive Pulmonary Fibrosis: A Subgroup Analysis of the FIBRONEER-ILD Trial
Steven D. Nathanh-index 15, Toby M. Maher, Shervin Assassi, Dirk Lievens, Susanne Stowasser, Hui Gu, Mary Beth Scholandh-index 5
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Purpose In the FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis (PPF), nerandomilast reduced decline in forced vital capacity (FVC) versus placebo, with benefits on clinical outcomes and favorable safety and tolerability. We present the effects of nerandomilast in US patients. Methods Patients were randomized to receive nerandomilast 9 mg bid, nerandomilast 18 mg bid, or placebo, stratified by nintedanib use and HRCT pattern. In the US subgroup, we assessed change in FVC (mL) at week 52; time-to-event endpoints over the whole trial; and adverse events over the whole trial. Results Of 1176 patients, 139 (11.8%) were from the US. In the US patients, adjusted mean (SE) changes in FVC (mL) at week 52 were − 160.4 (35.7) with placebo, − 115.2 (38.6) with nerandomilast 9 mg bid (difference vs. placebo 45.2 [95% CI: −57.8, 148.2]), and − 53.4 (37.3) with nerandomilast 18 mg bid (difference vs. placebo 107.0 [95% CI: 6.2, 207.9]). The hazard ratios (95% CI) for time to first acute exacerbation of ILD, hospitalization for respiratory cause, or death were 0.88 (0.42, 1.81) for nerandomilast 9 mg bid and 0.52 (0.23, 1.18) for nerandomilast 18 mg bid versus placebo. Adverse events led to treatment discontinuation in 14.0, 11.4 and 8.9% of the placebo, nerandomilast 9 mg bid and nerandomilast 18 mg bid groups, respectively. Conclusion In the FIBRONEER-ILD trial, the effects of nerandomilast in US patients were consistent with the overall population, with a reduction in FVC decline, numerically reduced risk of adverse clinical outcomes, and favorable safety and tolerability.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Steven D. Nathan has the highest h-index among the authors (15).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (22)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 2 more references
A free account opens the rest of the citing papers and references on every paper’s page.